NewAmsterdam Pharma reports Q1 net loss $39.5M; cash $808.5M; EMA submission on track for 2H25

NewAmsterdam Pharma Co N.V.

2025-Q1 EPS reported -$0.34 revenue$2,978,000

Cash $808.5M at Mar 31, 2025, down from $834.2M at Dec 31, 2024.
Net loss $39.5M vs $93.8M YoY; revenue $3.0M vs $1.4M.
EMA submission expected 2H25 by partner Menarini; PREVAIL CVOT enrollment completed.
Adele Gulfo appointed to Board of Directors in April 2025.
R&D expenses $44.8M; SG&A $27.2M, up due to commercial launch prep.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.